dplane clearly addresses that concern in his assessment, i.e. years of historical evidence of consistency of product production and clincal use. On that basis perhaps it is you who needs to "have another look".
- Forums
- ASX - By Stock
- Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
dplane clearly addresses that concern in his assessment, i.e....
-
- There are more pages in this discussion • 373 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 87395 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 274051 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 1.000 |
5 | 23430 | 0.990 |
4 | 52000 | 0.985 |
3 | 6800 | 0.980 |
2 | 12101 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 15867 | 1 |
0.990 | 25 | 1 |
1.000 | 50677 | 3 |
1.005 | 57507 | 4 |
1.010 | 59403 | 3 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online